JP2014522868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522868A5 JP2014522868A5 JP2014523080A JP2014523080A JP2014522868A5 JP 2014522868 A5 JP2014522868 A5 JP 2014522868A5 JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014522868 A5 JP2014522868 A5 JP 2014522868A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- protein
- acid sequence
- amino acid
- chimeric cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims 33
- 238000000034 method Methods 0.000 claims 27
- 102000004127 Cytokines Human genes 0.000 claims 23
- 108090000695 Cytokines Proteins 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 15
- 238000005349 anion exchange Methods 0.000 claims 9
- 238000005341 cation exchange Methods 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 4
- 238000012784 weak cation exchange Methods 0.000 claims 4
- 241000588724 Escherichia coli Species 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 238000010828 elution Methods 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 238000002372 labelling Methods 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 239000012149 elution buffer Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 shipment Substances 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000011534 wash buffer Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000000919 ceramic Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513453P | 2011-07-29 | 2011-07-29 | |
| US61/513,453 | 2011-07-29 | ||
| US201261591727P | 2012-01-27 | 2012-01-27 | |
| US61/591,727 | 2012-01-27 | ||
| PCT/US2012/048631 WO2013019652A1 (en) | 2011-07-29 | 2012-07-27 | Purified proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014522868A JP2014522868A (ja) | 2014-09-08 |
| JP2014522868A5 true JP2014522868A5 (enExample) | 2015-09-17 |
Family
ID=46682907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523080A Pending JP2014522868A (ja) | 2011-07-29 | 2012-07-27 | 精製タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140341843A1 (enExample) |
| EP (1) | EP2736524A1 (enExample) |
| JP (1) | JP2014522868A (enExample) |
| CN (1) | CN104066439A (enExample) |
| AU (1) | AU2012290379A1 (enExample) |
| BR (1) | BR112014002173A2 (enExample) |
| CA (1) | CA2843197A1 (enExample) |
| RU (1) | RU2014107743A (enExample) |
| SG (1) | SG10201606218WA (enExample) |
| WO (1) | WO2013019652A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ605928A (en) | 2010-07-29 | 2015-02-27 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
| ES2884813T3 (es) * | 2013-03-13 | 2021-12-13 | Buzzard Pharmaceuticals AB | Formulaciones de citoquina quimérica para administración ocular |
| AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| ES2810813T3 (es) * | 2014-01-24 | 2021-03-09 | Am Pharma Bv | Procesamiento para recuperación y purificación de una fosfatasa alcalina |
| TW201538178A (zh) * | 2014-03-13 | 2015-10-16 | Eleven Biotherapeutics Inc | 生產於吹氣成型充塡密封容器內穩定的嵌合型細胞激素蛋白質配方之方法 |
| JP6949711B2 (ja) * | 2014-10-23 | 2021-10-20 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | ペプチドバリアントを含む医薬組成物及びその使用方法 |
| TW201702380A (zh) * | 2015-02-27 | 2017-01-16 | 再生元醫藥公司 | 宿主細胞蛋白質修飾 |
| CN104710527B (zh) * | 2015-02-28 | 2018-08-24 | 苏州金盟生物技术有限公司 | 一种生物制品的内毒素去除方法 |
| KR102617148B1 (ko) * | 2016-08-15 | 2023-12-26 | 제넨테크, 인크. | 비이온성 계면활성제 및 폴리펩티드를 포함하는 조성물에서 비이온성 계면활성제를 정량화하기 위한 크로마토그래피 방법 |
| EP4142792A4 (en) | 2020-05-01 | 2024-11-27 | Kashiv Biosciences, LLC | An improved process of purification of protein |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| JP2799483B2 (ja) * | 1988-03-09 | 1998-09-17 | 大塚製薬株式会社 | インターロイキン−１β組成物の安定化方法 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| DK0502956T3 (da) * | 1989-11-29 | 1997-10-20 | Amgen Boulder Inc | Fremstilling af en rekombinant human interleukin-1-inhibitor. |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| HU219445B (hu) * | 1992-09-17 | 2001-04-28 | Amgen Inc. | Interleukin-1 inhibitorokat tartalmazó, stabil gyógyszerkészítmények és eljárás előállításukra |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| AU717003B2 (en) * | 1996-06-07 | 2000-03-16 | Gruppo Lepetit S.P.A. | Process for the purification of human interleukin-1 receptor antagonist from recombinant E. coli |
| ATE406176T1 (de) * | 1996-12-06 | 2008-09-15 | Amgen Inc | Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| TR201816556T4 (tr) * | 2004-04-02 | 2018-11-21 | Swedish Orphan Biovitrum Ab Publ | Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler |
| EP1781684A4 (en) * | 2004-08-25 | 2008-05-21 | Amprotein Corp | NEW CHIMERE POLYPEPTIDE AND USE THEREOF |
| CA2589802A1 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
| CN101970678B (zh) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | 具有增加的体内和/或体外稳定性的生物学活性蛋白 |
| WO2009023270A2 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| WO2011063195A2 (en) * | 2009-11-20 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Purification of modified cytokines |
| NZ605928A (en) * | 2010-07-29 | 2015-02-27 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
| WO2012103240A2 (en) * | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
-
2012
- 2012-07-27 RU RU2014107743/10A patent/RU2014107743A/ru not_active Application Discontinuation
- 2012-07-27 SG SG10201606218WA patent/SG10201606218WA/en unknown
- 2012-07-27 CN CN201280046036.2A patent/CN104066439A/zh active Pending
- 2012-07-27 AU AU2012290379A patent/AU2012290379A1/en not_active Abandoned
- 2012-07-27 EP EP12748087.9A patent/EP2736524A1/en not_active Withdrawn
- 2012-07-27 WO PCT/US2012/048631 patent/WO2013019652A1/en not_active Ceased
- 2012-07-27 JP JP2014523080A patent/JP2014522868A/ja active Pending
- 2012-07-27 BR BR112014002173A patent/BR112014002173A2/pt not_active IP Right Cessation
- 2012-07-27 CA CA2843197A patent/CA2843197A1/en not_active Abandoned
- 2012-07-27 US US14/235,777 patent/US20140341843A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014522868A5 (enExample) | ||
| Timmins et al. | Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4 | |
| US8329871B2 (en) | Process of purifying coagulation factor VIII | |
| US20180265895A1 (en) | Modified cas9 compositions and methods of use | |
| CN105175548B (zh) | 重组人血管内皮生长因子受体-抗体融合蛋白的纯化方法 | |
| JP7270085B2 (ja) | ナノ粒子製剤 | |
| US20090247735A1 (en) | Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers | |
| US20160251636A1 (en) | New methods to produce active tert | |
| JP2010529958A5 (enExample) | ||
| RU2014107743A (ru) | Очищенные белки | |
| JP2009273427A (ja) | 組換え体ヒトｆｓｈの製造方法 | |
| RU2019109975A (ru) | Способы очистки антител | |
| JP2008054693A (ja) | 酵母宿主から真性のｉｇｆを精製するための方法 | |
| EP3325614A1 (en) | Methods for purifying adenovirus vectors | |
| Fujiwara et al. | Extraction and purification of human interleukin-10 from transgenic rice seeds | |
| JP6232130B2 (ja) | ダルベポエチンアルファの精製方法 | |
| Eckhardt et al. | Purification of oncolytic measles virus by cation-exchange chromatography using resin-based stationary phases | |
| CA3014567C (en) | Method for producing activated hepatocyte growth factor (hgf) | |
| CA2956316C (en) | Method for purifying antibodies | |
| US20200361985A1 (en) | Method for purifying a sulfatase protein | |
| US9598687B2 (en) | Methods for processing coagulation factors | |
| US20250215050A1 (en) | Compositions and methods for purifying biological fluids | |
| Balagurunathan et al. | Enhancement of stability of recombinant streptokinase by intracellular expression and single step purification by hydrophobic interaction chromatography | |
| US11919924B1 (en) | Methods of purifying and producing an adalimumab antibody | |
| JP5750471B2 (ja) | 組換え体ヒトｆｓｈの製造方法 |